Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Linkoeping University
With
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases worldwide and is particularly common among individuals with type 2 diabetes. While many people remain stable over time, some develop progressive liver fibrosis, cirrhosis, hepatocellular carcinoma, and other serious liver-related complications. Reliable methods for identifying patients at greatest risk of disease progression remain limited. EPSOMIP2 is a prospective observational follow-up study of participants who were previously enrolled in the EPSONIP study (NCT03864510) between 2019 and 2023. In the original study, 317 individuals with type 2 diabetes from primary healthcare centers in Östergötland, Sweden, underwent detailed evaluation of liver disease, metabolic health, physical activity, and body composition. Participants who completed the original study are invited to undergo a new assessment approximately 6 years after their initial evaluation. The follow-up examination includes clinical assessment, blood and urine sampling, vibration-controlled transient elastography, magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), magnetic resonance elastography (MRE), body composition analysis, questionnaires, physical activity measurements, blood pressure assessments, and biobanking. By comparing the follow-up findings with data collected during the original EPSONIP study, researchers aim to characterize the long-term natural history of MASLD in type 2 diabetes. The study will evaluate prevalence, progression, and regression of hepatic steatosis and liver fibrosis, and investigate associations with physical activity, body composition, genetic variants, hypertension, obstructive sleep apnea, and other metabolic risk factors. The study will also investigate the occurrence of clinically significant liver-related outcomes, including decompensated liver disease, hepatocellular carcinoma, liver transplantation, and liver-related mortality. In addition, health-economic analyses will be performed to evaluate strategies for MASLD management and risk stratification. The overall aim of EPSOMIP2 is to improve understanding of the long-term course of MASLD in individuals with type 2 diabetes and to identify factors associated with progression to advanced liver disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
